Acerus Drug Patent Portfolio
Acerus owns 1 orange book drug protected by 5 US patents Given below is the list of Acerus's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11090312 | Methods of treating hypogonadism with transnasal testerosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event | 17 Mar, 2034 | Active |
US8574622 | Controlled release delivery system for nasal applications | 04 Feb, 2024 | Expired |
US8784869 | Controlled release delivery system for nasal applications and methods of treatment | 04 Feb, 2024 | Expired |
US8784882 | Controlled release delivery system for nasal applications and method of treatment | 04 Feb, 2024 | Expired |
US8877230 | Controlled release delivery system for nasal applications | 04 Feb, 2024 | Expired |
Latest Legal Activities on Acerus's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Acerus.
Activity | Date | Patent Number |
---|---|---|
Change in Power of Attorney (May Include Associate POA)
Critical
| 02 Jul, 2024 | US11090312 |
Email Notification
Critical
| 02 Jul, 2024 | US11090312 |
Email Notification
Critical
| 14 Apr, 2022 | US8574622 |
Mail Certificate of Correction Memo | 13 Apr, 2022 | US8574622 |
Certificate of Correction Memo | 07 Apr, 2022 | US8574622 |
Payment of Maintenance Fee, 8th Yr, Small Entity | 15 Feb, 2022 | US8877230 |
Payment of Maintenance Fee, 8th Yr, Small Entity | 12 Jan, 2022 | US8784869 |
Recordation of Patent Grant Mailed
Critical
| 17 Aug, 2021 | US11090312 |
Patent Issue Date Used in PTA Calculation
Critical
| 17 Aug, 2021 | US11090312 |
Payment of Maintenance Fee, 8th Yr, Small Entity | 12 Aug, 2021 | US8784882 |
Email Notification
Critical
| 29 Jul, 2021 | US11090312 |
Issue Notification Mailed
Critical
| 28 Jul, 2021 | US11090312 |
Dispatch to FDC | 13 Jul, 2021 | US11090312 |
Workflow - Drawings Finished | 09 Jul, 2021 | US11090312 |
Mail PUB other miscellaneous communication to applicant | 08 Jul, 2021 | US11090312 |
Acerus's Family Patents
Acerus drugs have patent protection in a total of 22 countries. It has a significant patent presence in the US with 58.2% of its patents being US patents. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Acerus Drug List
Given below is the complete list of Acerus's drugs and the patents protecting them.
1. Natesto
Natesto is protected by 5 patents, out of which 4 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11090312 | Methods of treating hypogonadism with transnasal testerosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
17 Mar, 2034
(9 years from now)
| Active |
US8574622 | Controlled release delivery system for nasal applications |
04 Feb, 2024
(10 months ago)
| Expired |
US8784869 | Controlled release delivery system for nasal applications and methods of treatment |
04 Feb, 2024
(10 months ago)
| Expired |
US8784882 | Controlled release delivery system for nasal applications and method of treatment |
04 Feb, 2024
(10 months ago)
| Expired |
US8877230 | Controlled release delivery system for nasal applications |
04 Feb, 2024
(10 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Natesto's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List